BioMedNewsBreaks

WednesdayFeb 16, 2022 1:47 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. According to the piece, InMed achieved Q222 financial results that reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3 million, all cannabichromene (“CBC”). “As of January, it also began selling cannabicitran (‘CBT’) to the health and wellness market,” notes the report. “The now-completed BayMedica acquisition boosts its product portfolio for rare cannabinoids and rounds…

Continue Reading

WednesdayFeb 16, 2022 1:28 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, noting that these second-generation molecules address delivery and stability concerns with the first-generation compounds. According to the company, its research findings show the potential for a psilocin analog that may be considered a heart-safe microdose drug, which is a substance consumed at a low enough…

Continue Reading

TuesdayFeb 15, 2022 3:21 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Distinctive with Phased Approach to Novel Therapeutics Development

Mydecine (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent Bell2Bell Podcast episode in which its co-founder, chairman and CEO Josh Bartch shared the company’s goals for the new year. Of note was Mydecine’s phased approach, which entails understanding the imperfections of initial formulations and then improving aspects such as the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc., in order to make them more effective. This approach has set the company apart from its peers. A…

Continue Reading

TuesdayFeb 15, 2022 12:32 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his new role, Griffin will manage the commercialization of BayMedica’s health and wellness business including existing products as well as the launch of new products. Griffin brings a rich background to this position, having a proven track record as a veteran sales executive. He has served in several senior positions in Fortune 500 companies, including most recently as VP of sales…

Continue Reading

MondayFeb 14, 2022 2:26 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies

InMed Pharmaceuticals (NASDAQ: INM) understands the immense potential of rare cannabinoids and sees them as having applications as wide as cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), variants of cannabinoids that make up most of the content in cannabis plants. Studies suggest that rare cannabinoids could offer more potent medical benefits than CBD and without the psychoactive attribute of THC, representing a huge market. “However, the industry wide problem has always been to obtain the production scales necessary for cost-effective commercialization of such compounds, while also ensuring the purity and consistency that can be difficult at even low volumes. The answer is…

Continue Reading

MondayFeb 14, 2022 11:23 am

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Reports Financial Results, Business Updates for Q3 2022

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, has released its Q3 financial results and business updates. The company noted that, for the three-month period ending Dec. 31, 2021, highlights included the shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its United-Kingdom licensee, MySugarWatch Limited; the appointment of Dr. Arash Ghadar as COO; and the launch of Miboko, a new metabolic health program using a wearable glucose sensor along with an AI mobile application. The company also reported that earlier this month Tiger Partners Trading LLC…

Continue Reading

FridayFeb 11, 2022 12:36 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Appoints New COO in Readiness for Manufacturing and Distribution Scale-Up, Commercialization Phase of Growth

Nemaura Medical (NASDAQ: NMRD) recently appointed Dr. Arash Ghadar as its chief operating officer. Dr. Ghadar brings decades of health care and technical experience to Nemaura, including from his previous role as technical director at Datalink Electronics and his current director role at Medilink Midlands. “Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations… He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily within a contract design and…

Continue Reading

ThursdayFeb 10, 2022 12:12 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Receives Notice of Allowance by USPTO for Smart Medical Inhaler System

RYAH Group (CSE: RYAH) today announced that the U.S. Patent and Trademark Office (the “USPTO”) has issued a Notice of Allowance for U.S. patent application number 15/924,172, filed in respect of the company's IoT-powered, Smart Medical Inhaler system by its wholly owned subsidiary, Potbotics Inc. The hybrid conduction and convection RYAH Smart Medical Inhaler was recently granted Medical Device Certification under ISO 13485:2016/MDSAP and EN ISO 13485:2016 standards for both its hardware and software. “Receiving this Notice of Allowance by the USPTO on our Smart Medical Inhaler is the result of dedication and great effort by all of our product…

Continue Reading

ThursdayFeb 10, 2022 12:03 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release Q2 Financial Report, Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced that it will report its second-quarter financial results next week on Feb. 15, 2022; the results will cover the period ending Dec. 31, 2021. The company has scheduled a conference call and webcast to discuss the report; the call will be held Feb. 15, 2021, at 2 p.m. ET. Those interested can dial +1 (855) 605-1745 (United States and Canada) or +1 (914) 987-7959 (international) using conference ID 8645175. In addition, the company’s full financial statements and related MD&A along with a replay of the…

Continue Reading

TuesdayFeb 08, 2022 1:37 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company aiming to transform the treatment of mental health and addiction disorders. The company today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program (“SAP”), which allows health care providers to request specific drugs for approved patients who have not responded to other treatment options. Available to Mydecine through its exclusive agreement with Applied Pharmaceutical Innovation (“API”), the licensed dealer facility contains a unique research and development infrastructure as well as a manufacturing facility in Edmonton, Canada. With the…

Continue Reading